SOLIBEGRON- 50
For An Ameliorative Effect In OAB

Composition : Solifenacin 5mg + Mirabegron ER 50mg

Form : Tablets / Pack : 10 X 10's / Type : ALU ALU

Description : Mirabegron and solifenacin combination treatment for OAB symptoms was well tolerated over 12 mo and led to efficacy improvements over each mono-therapy. This innovative combination is a treatment option that could become widely used in the clinic - Eur. Urol.2018 Oct; 74(4):501-509. In conclusion, in the present study of patients with wet OAB, combined therapy with solifenacin & mirabegron provided improvements in efficacy compared with the respective monotherapies, with effect sizes generally consistent with an additive effect - BJU International, 2018.

View more products with following salts

TAMSOPROST- 0.4
DELAYS PROSTATIC SURGERY

Composition : Tamsulosin 0.4mg

Form : Tablets / Pack : 10x10’s / Type : AA

Description : Tamsulosin is a more selective α1A subtype antagonist, which maintains the α-antagonist effect on the prostatic capsule and bladder neck but has less of an effect on the vascular system and blood pressure. In fact, tamsulosin is ineffective and not indicated in the treatment of hypertension. Tamsulosin has a favorable side effect profile in regard to problems related to hypotension and dizziness compared to those of terazosin and doxazosin. Clinical trials of 1 year or longer with tamsulosin show high tolerability for the 0.4 mg dose and no significant interaction with other antihypertensive medications- Rev Urol. 2005; 7(Suppl 4): S13–S21.

View more products with following salts

ALSOLIZER
Maintains Acid-Base Balance

Composition : Disodium Hydrogen Citrate 1.4gm/ 5ml SUGAR FREE

Form : Syrup / Pack : 100ml / Type : PVC Bottle

Description : Disodium Hydrogen Citrate is an acid salt of citric acid used as an antioxidant as well as to improve the effects of other antioxidants. Used as an acidity regulator and sequestrant,thus known as systemic alkalinizer, make the urine less acidic , helps the kidneys get rid of uric acid, helping to prevent gout and certain types of kidney stones. Also prevent and treat certain metabolic problems (acidosis) caused by kidney disease and alleviate discomfort from certain urinary tract. infections

View more products with following salts

Tamsoprost –D
Treats BPH From Both The End

Composition : Tamsulosin 0.4mg & Dutasteride 0.5mg

Form : Tablets / Pack : 10 X 10s / Type : ALU ALU

Description : Combination treatment with Tamsulosin & Dutasteride is significantly superior to Tamsulosin & Dutasteride monotherapy in terms of symptom improvement and reduction of relative risk of BPH clinical progression. Further shown to be a safe treatment and the adverse events observed were consistent with previous experience. Combination therapy should only be used when long-term treatment (more than 12 months) is intended - Therapeutic advances in urology; 2016 Feb; 8(1): 19-28.

View more products with following salts

Mictura-4
Reduces the Need for BPH Related Surgery

Composition : Silodosine 4mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Silodosin, is a medication for the symptomatic treatment of benign prostatic hyperplasia. It acts as an α1A-adrenoceptor antagonist with high uroselectivity (selectivity for the prostate), has been approved by the FDA since October 2008 at a recommended dose of 8 mg orally once daily. Clinical studies have shown that this selective α1A-AR is very attractive and more effective than placebo for voiding and storage symptoms in LUTS arising from BPH. Silodosin has excellent early efficacy, and is at least as effective as for other α1-blockers. Silodosin distinguishes itself by a strong effect not only on symptoms but also on obstruction as measured by pressure flow studies- Drug Des Devel Ther. 2010; 4: 291–297.

View more products with following salts

Mictura-8
Reduces the Need for BPH Related Surgery

Composition : Silodosine 8mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Silodosin, is a medication for the symptomatic treatment of benign prostatic hyperplasia. It acts as an α1A-adrenoceptor antagonist with high uroselectivity (selectivity for the prostate), has been approved by the FDA since October 2008 at a recommended dose of 8 mg orally once daily. Clinical studies have shown that this selective α1A-AR is very attractive and more effective than placebo for voiding and storage symptoms in LUTS arising from BPH. Silodosin has excellent early efficacy, and is at least as effective as for other α1-blockers. Silodosin distinguishes itself by a strong effect not only on symptoms but also on obstruction as measured by pressure flow studies- Drug Des Devel Ther. 2010; 4: 291–297.

View more products with following salts

Mictura-DS
Reduces the Need for BPH Related Surgery

Composition : Dutasteride 0.5mg & Silodosine 4mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Dutasteride inhibits the conversion of testosterone to Di-hydrotestosterone (DHT). Testosterone is converted to DHT by the enzyme 5- Alpha-reductase, which exists in two iso-forms.The type-2 iso-enzyme is primarily active in the reproductive tissues, while type- 1 iso-enzyme is responsible for testosterone conversion in the skin and liver. Dutasteride competitively & specificifically inhibits both type of 5- alpha-reductase. Silodosin belongs to a class of selective alpha-1A adrenergic receptor blockers, works by blocking the alpha-1A adrenergic receptors located in the muscles of prostate gland, urinary bladder & urethra and hence relaxes these muscles, resulting in an improvement in urine flow & a reduction in BPH symptoms. Silodosin has a very high uro-selectivity i.e. selectivity for the prostate.

View more products with following salts

Sobitab- 500
The Quick Acting Antacid since Then

Composition : Sodium Bi Carbonate 500mg

Form : Tablets / Pack : 10's / Type : Blister

Description : Randomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m2) and serum bicarbonate 16 to 20 mmol/L to either supplementation with oral sodium bicarbonate or standard care for 2 yr. The primary end points were rate of CrCl decline, the proportion of patients with rapid decline of CrCl (>3 ml/min per 1.73 m2/yr), and ESRD (CrCl <10 ml/min). Secondary end points were dietary protein intake, normalized protein nitrogen appearance, serum albumin, and mid-arm muscle circumference. Compared with the control group, decline in CrCl was slower with bicarbonate supplementation (5.93 versus 1.88 ml/min 1.73 m2; P < 0.0001). Patients supplemented with bicarbonate were significantly less likely to experience rapid progression (9 versus 45%; relative risk 0.15; 95% confidence interval 0.06 to 0.40; P < 0.0001). Similarly, fewer patients supplemented with bicarbonate developed ESRD (6.5 versus 33%; relative risk 0.13; 95% confidence interval 0.04 to 0.40; P < 0.001). Nutritional parameters improved significantly with bicarbonate supplementation, which was well tolerated. This study demonstrates that bicarbonate supplementation slows the rate of progression of renal failure to ESRD and improves nutritional status among patients with CKD- Journal of the American Society of Nephrology 2009.

View more products with following salts

Sobitab-1000
The Quick Acting Antacid since Then

Composition : Sodium Bi Carbonate 1000mg

Form : Tablets / Pack : 10's / Type : Blister

Description : Randomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m2) and serum bicarbonate 16 to 20 mmol/L to either supplementation with oral sodium bicarbonate or standard care for 2 yr. The primary end points were rate of CrCl decline, the proportion of patients with rapid decline of CrCl (>3 ml/min per 1.73 m2/yr), and ESRD (CrCl <10 ml/min). Secondary end points were dietary protein intake, normalized protein nitrogen appearance, serum albumin, and mid-arm muscle circumference. Compared with the control group, decline in CrCl was slower with bicarbonate supplementation (5.93 versus 1.88 ml/min 1.73 m2; P < 0.0001). Patients supplemented with bicarbonate were significantly less likely to experience rapid progression (9 versus 45%; relative risk 0.15; 95% confidence interval 0.06 to 0.40; P < 0.0001). Similarly, fewer patients supplemented with bicarbonate developed ESRD (6.5 versus 33%; relative risk 0.13; 95% confidence interval 0.04 to 0.40; P < 0.001). Nutritional parameters improved significantly with bicarbonate supplementation, which was well tolerated. This study demonstrates that bicarbonate supplementation slows the rate of progression of renal failure to ESRD and improves nutritional status among patients with CKD- Journal of the American Society of Nephrology 2009.

View more products with following salts